Screener
CRISPR Therapeutics CRSP CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other liabilities, net | (199) | (10,541) |
| Net cash used in operating activities | (108,897) | (53,947) |
| Investing activities: | ||
| Purchase of property, plant and equipment | (504) | (206) |
| Investment in equity securities | (4,615) | (5,000) |
| Purchases of marketable securities | (746,089) | (200,730) |
| Maturities of marketable securities | 192,759 | 186,181 |
| Sales of marketable securities | 147,706 | — |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's capex?
- CRISPR Therapeutics (CRSP) reported capex of $504K in Q1 2026.
- How has CRISPR Therapeutics's capex changed year-over-year?
- CRISPR Therapeutics's capex increased by 144.7% year-over-year, from $206K to $504K.
- What is the long-term trend for CRISPR Therapeutics's capex?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's capex has grown at a -67.5% compound annual growth rate (CAGR), from $81.71M to $914K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about CRISPR Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude